─────────────────
B I O - T E C H S Y S T E M S , I N C .
Market Research in the Health Care Field
13900 Panay Way, #R221
Marina Del Rey, California 90292
November 1, 2012
Tel: (424) 228-5793 Fax: (424) 228-5801
E-Mail: MBurns@biotechsystems.com
Web Site: www.biotechsystems.com
───────────────────────────────────────────────────────────────────────────────
FOR IMMEDIATE RELEASE Contact: Marvin Burns
Tel: (424) 228-5793
Fax: (424) 228-5801
BIO-TECH SYSTEMS ANNOUNCES A NEW RADIOPHARMACEUTICAL REPORT:
Report 350: THE MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS
──────────────────────────────────────────────────────────────
MAJOR GROWTH PROSPECTS FOR THERAPEUTIC RADIOPHARMACEUTICALS, LARGE
INTERNATIONAL INVESTMENTS IN NEW PRODUCTS, MORE EFFECTIVE TARGETING
BEING DEVELOPED, EMPHASIS ON ALPHA EMITTING PRODUCTS, NEW INDUSTRY
ALLIANCES AND PARTNERSHIPS, MARKET TRENDS AND FORECASTS TO 2020
Bio-Tech Systems Inc. announces the publication of a new report with detailed analysis of the markets for therapeutic radiopharmaceuticals. The report has a strong focus on new products and technology and emerging market opportunities. This includes applications in bone cancer, neuroendocrine cancer, abdominal cancers, leukemia and blood cancers, prostate cancer, pancreatic cancer and cancers that are resistant to traditional therapies. The report also analyzes the markets for irradiated microspheres for liver cancer and bone pain palliation.
There has been an increase in research activity to expand applications for therapeutic radiopharmaceuticals with serious commitment to the technology and definite plans to bring these products to market. There are significant advantages to delivering targeted radiation to malignant cells with therapeutic radiopharmaceuticals compared with conventional therapies. It allows one to seek out and destroy diseased cells while protecting healthy cells in the vicinity. In addition, the new generation of therapeutic radiopharmaceuticals employs more advanced targeting with antibodies and peptides linked to therapeutic isotopes that are optimized for each application.
There has also been a significant improvement in reimbursement recently and more liberal FDA policies regarding the use of these products. This has substantially improved the economic climate for investment and created more business opportunities in this field. There are 19 radiotherapy products that are either approved or in development. Many of the research products are being financed by international companies with significant resources and commitment to the success of these ventures. This shows confidence in the clinical potentials of these products and the opportunity to develop a commercial platform that will sustain continued growth both in the
U.S. and internationally. It also provides a natural link between U.S. and international markets.
As these products are introduced, it will stimulate the pace of development and accelerate introduction of new products in the pipeline.
1 ---more---

Therapeutic Radiopharmaceuticals: Market Analysis and Future Prospects
U.S. sales of therapeutic radiopharmaceuticals were $244.9 million in 2012. Rapid growth is anticipated over the next 5-6 years. By 2020, therapeutic product sales should reach $5.8 billion, with high continuing growth beyond that time. This will be based on the introduction of new therapeutic radiopharmaceuticals for treating bone cancer, neuroendocrine cancer, metastatic abdominal cancers, leukemia and blood cancers, prostate cancer and other persistent cancers.
These drugs will be used in conjunction with traditional therapies, enhancing their effectiveness, with better specificity and reduced side effects. Many of the new products will utilize isotopes with more focused capabilities, reducing the effect on neighboring healthy cells. Use of these new agents will reduce treatment time and accelerate recovery for many patients. It will also offer an attractive investment opportunity for many of the companies and venture groups supporting these programs.
Treating cancer with drugs is a trial and error process in most cases. Some patients may respond better to one drug than another, even though superficial indications and symptoms are the same.
This allows the clinician to utilize new therapeutic drugs with the prospect that they will produce a positive response. As new therapeutic radiopharmaceuticals are introduced, it will stimulate the development of a large array of related products targeted to many different types of cancer.
Increased international participation in this field will assure a steady supply of isotopes from available stockpiles in Europe and other parts of the world that are less subject to restrictions applicable to U.S. sources. This will provide stability in this field and increase the available options in selecting isotopes with optimum capabilities.
International firms will also be well positioned to provide the resources necessary to support joint ventures and development programs in the U.S. This will augment the technological capabilities and experience that is available to develop effective new radiotherapeutic products.
Marvin Burns is president of Bio-Tech Systems, Inc., a firm that focuses on market research in the healthcare field. Burns specializes in market evaluation, where technological and scientific insight is important. The company has prepared numerous market research reports on diagnostic and therapeutic radiopharmaceuticals, brachytherapy, contrast media, interventional cardiology and medical imaging, which have been widely distributed. Burns has also served as a consultant to many international firms and venture groups in these fields. He has also been Technology
Editor of Future Oncology, a publication widely circulated in the pharmaceutical and biotechnology industry reporting on new developments in cancer diagnosis and treatment. Burns is a graduate of MIT and Harvard Business School’s advanced management program. He has prepared over 100 publications and has 15 patents and invention disclosures. Prior to forming
Bio-Tech Systems, he was employed by firms in life sciences, bioinstrumentation and medical imaging fields in general management, marketing and product development. He was also a hospital administrator in charge of professional and technical services including medical imaging, clinical laboratories, therapy services, and materials management.
2 ---more---

Report 350: THERAPEUTIC RADIOPHARMACEUTICALS: REPORT CONTENTS
SECTION I: Market Status, Trends and Forecasts
Analysis of current and emerging markets for therapeutic radiopharmaceuticals. Market prospects by product and disease category. New products in the pipeline, projections for FDA approval and sales forecasts in all categories to 2020. This includes:

Analysis of market prospects for targeted radiotherapy agents. Applications include lymphoma, neuroendocrine cancer, bone cancer, abdominal cancers, leukemia and blood cancers, prostate cancer, irradiated microspheres for liver cancer and other cancers.

Projections for new products using novel targeting technologies and radioisotopes optimized for the application. Market analysis and sales projections.

Discussion of new corporate alliances and international support and sponsorship of development programs.
SECTION II: Market Analysis and Forecasts by Product Group

Sales forecasts by procedure type and product category with rationale for the projections.

Discussion of market prospects for new technologies and targeted products.
SECTION III: Analysis of Procedure Volume

Discussion of incidence of disease and relationship to potential radiotherapy procedures.
Forecast procedure volume by disease category from 2012-2020 with discussion of rationale for these projections.

Methodology for collecting procedure data and forecasting future growth. Evaluation of different data sources with rationale for interpreting the results.
SECTION IV: Radiopharmaceutical Products and Technology

Technical principles and functional characteristics of therapeutic radiopharmaceuticals.

New options in selecting therapeutic isotopes for specific applications. Discussion of new therapeutic radiopharmaceuticals in development, with analysis of technological prospects and potential applications. .

Analysis of product characteristics, performance benefits and trade-offs relative to various therapeutic applications.
SECTION V: Current Developments and Emerging Technology

Analysis of new products in the pipeline, mechanism of action and comparative benefits

Technological approach, clinical progress and competitive opportunities
SECTION VI: End-User Analysis

Analysis of end-user groups and comparative requirements for radiotherapy products.

Procedure mix and product utilization in hospitals and clinics.
SECTION VII: Company Profiles

Background information on companies in the field and review of recent performance.

Discussion of each company's market activities and management strategies.
3

RADIOTHERAPEUTIC PRODUCTS
APPROVED AND IN DEVELOPMENT
HISTORIC AND FORECAST PROCEDURE
GROWTH FOR THERAPEUTIC
RADIOPHARMACEUTICALS FROM
2006-2020
HISTORIC AND FORECAST SALES
GROWTH FOR THERAPEUTIC
RADIOPHARMA-CEUTICALS FROM
2006-2020
2012 THERAPEUTIC RADIOPHARMA-
CEUTICAL SALES SUMMARY BY
PROCEDURE CATEGORY AND PRODUCT
TYPE
2020 THERAPEUTIC RADIOPHARMA-
CEUTICAL SALES SUMMARY BY
PROCEDURE CATEGORY AND PRODUCT
TYPE
HISTORIC AND FORECAST TARGETED
RADIOTHERAPY PROCEDURES,
PROCEDURE GROWTH BY PRODUCT
GROUP FROM 2009-2020
HISTORIC AND FORECAST TARGETED
RADIOTHERAPY SALES, SALES GROWTH
BY PRODUCT CATEGORY FROM
2009-2020
HISTORIC AND FORECAST MARKET FOR
LYMPHOMA PRODUCTS, PROCEDURE
VOLUME AND SALES GROWTH FROM
2009-2020
MARKET FORECAST FOR BONE CANCER
THERAPEUTIC PRODUCTS, PROCEDURE
VOLUME AND SALES GROWTH FROM
2013-2020
MARKET FORECAST FOR
NEUROENDOCRINE CANCER THERAPY
PRODUCTS, PROCEDURE VOLUME AND
SALES GROWTH FROM 2013-2020
LIST OF EXHIBITS─THERAPEUTIC RADIOPHARMACEUTICALS
MARKET FORECAST FOR ALPHA
THERAPY PRODUCTS FOR LEUKEMIAS
AND BONE MARROW ABLATION FOR
STEM CELL TRANSPLANTATION,
PROCEDURE VOLUME AND SALES
GROWTH FROM 2013-2020
MARKET FORECAST FOR ALPHA
THERAPY PRODUCTS FOR METASTATIC
ABDOMINAL CANCERS INCLUDING
BREAST, OVARIAN, COLON, GASTRIC,
ENDOMETRIAL AND PANCREATIC,
PROCEDURE VOLUME AND SALES
GROWTH FROM 2013-2020
MARKET FORECAST FOR LIPID
TARGETING MULTIPLE SOLID TUMORS,
PROCEDURE VOLUME AND SALES
GROWTH FROM 2015-2020
MARKET FORECAST FOR ANTIBODY
TARGETED PANCREATIC CANCER,
PROCEDURE VOLUME AND SALES
GROWTH FROM 2014-2020
MARKET FORECAST FOR ANTIBODY
TARGETED PROSTATE CANCER,
PROCEDURE VOLUME AND SALES
GROWTH FROM 2014-2020
MARKET FORECAST FOR IRRADIATED
MICROSPHERES FOR LIVER CANCER,
SALES GROWTH AND PROCEDURE
VOLUME BY PRODUCT FROM 2009-2020
HISTORIC AND FORECAST MARKET
GROWTH FOR BONE PAIN PALLIATION,
SALES GROWTH AND PROCEDURE
VOLUME BY PRODUCT FROM 2009-2020
GROWTH OF RADIOTHERAPY
PROCEDURE VOLUME FROM 2012-2020
DIAGNOSTIC AND THERAPEUTIC
ISOTOPES
AVAILABLE ALPHA EMITTERS
4

LIST OF EXHIBITS─THERAPEUTIC PET RADIOPHARMACEUTICALS
CORRELATION BETWEEN TYPE AND
ENERGY OF CORPUSCULAR
RADIATION, AND THE RANGE OF
PENETRATION IN TISSUE
DECAY CHAIN OF RADIOISOTOPES
LEADING TO LEAD-212 AND
BISMUTH-212
NATURAL DECAY CHAIN OF
ACTINIUM-225 LEADING TO
BISMUTH-213
NATURAL DECAY CHAIN FOR
RADIUM-223 IN TREATMENT OF BONE
CANCER
BONE TUMOR TARGETING OF
ALPHARADIN WITH RADIUM-223
COMPARATIVE ALLOCATION OF
DIAGNOSTIC FACILITIES BY HOSPITAL
BED SIZE IN 2012
COMPARATIVE UTILIZATION
PARAMETERS FOR DIFFERENT
IMAGING MODALITIES IN 2012
DISTRIBUTION OF HOSPITAL
DIAGNOSTIC IMAGING PROCEDURES
IN THE U.S. BY HOSPITAL BED SIZE IN
2012
RELATIVE PROCEDURE VOLUME FOR
DIFFERENT IMAGING MODALITIES,
PERCENTAGE RELATIONSHIP BY
HOSPITAL BED SIZE IN 2012
RELATIVE ACTIVITY INDEX AMONG
DIFFERENT IMAGING MODALITIES
PROCEDURES PER BED PER YEAR BY
HOSPITAL BED SIZE IN 2012 v

ACTINIUM PHARMACEUTICALS
ADVANCED ACCELERATOR
APPLICATIONS (AAA)
ALGETA ASA
ALPHAMED INC.
AREVA MED
ATLAB PHARMA
BAYER HEALTHCARE
BIOGEN IDEC INC.
BIOSYNTHEMA CORP.
BIONUCLEONICS, INC.
CORNELL WEILL MEDICAL
CENTER (BZL BIOLOGICS)
CYTOGEN CORPORATION
(EUSA)
DRAXIMAGE DIV. OF
JUBILANT ORGANON
GE HEALTHCARE
COMPANY PROFILES INCLUDE
GLAXO SMITHKLINE CORP.
IMMUNOMEDICS, INC.
ISOTHERAPEUTICS GROUP
LANTHEUS MEDICAL IMAGING
MOLECULAR INSIGHT
PHARMACEUTICALS INC.
NORDION, INC.
NORTH STAR MEDICAL
RADIOISOTOPES
NOVELOS THERAPEUTICS INC.
SIRTEX MEDICAL LTD.
SPECTRUM
PHARMACEUTICALS
6

Report No. 350 – MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS
The report is priced at $9,500 plus $4,500 for a multi-user license.
Electronic PDF copies are available at no extra cost.
Please make check payable to: BIO-TECH SYSTEMS, INC.
For wire transfer, make deposit to:
BANK OF AMERICA, NEVADA
Post Office Box 98600
Las Vegas, Nevada 89193-8600
S.W.I.F.T. Code: BOFAUS3N (for International wire transfers)
ABA Routing No. 122 400 724
Account Name: BIO-TECH SYSTEMS, INC.
Account No. 5010 1469-1771
Mailing Information
Name______________________________Title:_____________________________________
Company_____________________________________________________________________
Address______________________________________________________________________
City _______________________ State ________Zip Code __________Country____________
Telephone_______________________________FAX_________________________________
E-Mail_______________________________________________
P.O. #______________________________Signature__________________________________
Credit Cards: VISA, MASTERCARD, AMEX (Check One)
Credit Card No._______________________________________________________________
Expiration: Month _______Year _____Name on Card:________________________________
Signature_____________________________________________________________________
Address for Credit Card Statements________________________________________________
____________________________________________________________________________
Return to:
BIO-TECH SYSTEMS, INC.
13900 Panay Way, #R221
Marina Del Rey, California 90292
Tel: (424) 228-5793 Fax: (424) 228-5801
E-Mail: MBurns@biotechsystems.com
7